Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3262
Source ID: NCT00929539
Associated Drug: Jtt-130
Title: Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type II Diabetes Mellitus
Interventions: DRUG: JTT-130|DRUG: JTT-130 Placebo
Outcome Measures: Primary: Change in glycosylated hemoglobin (HbA1c) levels, End of Study | Secondary: Safety and tolerability data, End of Study
Sponsor/Collaborators: Sponsor: Akros Pharma Inc.
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 496
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2009-06
Completion Date: 2010-07
Results First Posted:
Last Update Posted: 2013-02-04
Locations: Birmingham, Alabama, United States|Muscle Shoals, Alabama, United States|Scottsboro, Alabama, United States|Tucson, Arizona, United States|Encino, California, United States|Los Angeles, California, United States|Sacramento, California, United States|Spring Valley, California, United States|Valley Village, California, United States|Walnut Creek, California, United States|Waterbury, Connecticut, United States|Delray Beach, Florida, United States|Hialeah, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Ocala, Florida, United States|Sandy Springs, Georgia, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Erlanger, Kentucky, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Madisonville, Kentucky, United States|Paducah, Kentucky, United States|New Hyde Park, New York, United States|Greensboro, North Carolina, United States|Morehead City, North Carolina, United States|Statesville, North Carolina, United States|Cincinnati, Ohio, United States|Marion, Ohio, United States|Tulsa, Oklahoma, United States|Eugene, Oregon, United States|Portland, Oregon, United States|Charleston, South Carolina, United States|Greer, South Carolina, United States|North Charleston, South Carolina, United States|Bristol, Tennessee, United States|Austin, Texas, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Manassas, Virginia, United States|Richmond, Virginia, United States|Bellevue, Washington, United States|Olympia, Washington, United States|Oregon, Wisconsin, United States|Beroun, Czech Republic|Brno, Czech Republic|Ostrava, Czech Republic|Pardubice, Czech Republic|Prague, Czech Republic|Velke Hostice, Czech Republic|Satoraljaujhely, Hungary|Szikszo, Hungary|Eindhoven, Netherlands|Groningen, Netherlands|Arkhangelsk, Russian Federation|Moscow, Russian Federation|Nizhniy Novgorod, Russian Federation|St. Petersburg, Russian Federation
URL: https://clinicaltrials.gov/show/NCT00929539

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress